home / stock / mrns / mrns articles

MRNS Articles, Marinus Pharmaceuticals Inc. - From 06/06/24

Stock Information
Company Name: Marinus Pharmaceuticals Inc.
Stock Symbol: MRNS
Market: NASDAQ
Website: marinuspharma.com
Menu
MRNS MRNS Quote MRNS Short MRNS News MRNS Articles MRNS Message Board
Get MRNS Alerts

News, Short Squeeze, Breakout and More Instantly...
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Marinus Pharmaceuticals, Inc. (MRNS) | Benzinga

NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Marinus Pharmaceuticals, Inc. - MRNS | Benzinga

NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Marinus Pharmaceuticals, Inc. ("Mari...

Class Action Lawsuit Filed on Behalf of Marinus Pharmaceuticals, Inc. (MRNS) Investors – Nationally Ranked Investors' Rights Firm Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm | Benzinga

ATLANTA, June 06, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. ("Marinus" or...

Stockholder Alert: Robbins LLP Informs Investors that a Shareholder Has Filed a Class Action Against Marinus Pharmaceuticals, Inc. (MRNS) | Benzinga

SAN DIEGO, June 05, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of persons and ent...
MRNS INVESTOR NEWS: ROSEN, A LEADING LAW FIRM, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MRNS | Benzinga

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action laws...

Candel Reports Upbeat Data From Lung Cancer Study | Benzinga

Candel Therapeutics, Inc. (NASDAQ: CADL) announced overall survival data from a phase II study evaluating its lead investigational adenovirus immun...

Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday | Benzinga

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Analysts Question Commercial Viability of Marinus' IV Ganaxolone After Interim Analysis Miss | Benzinga

Monday, in an interim analysis of Marinus Pharmaceuticals Inc’s (NASDAQ:MRNS) phase 3 RAISE trial, evaluating intravenous (IV) gana...

S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March | Benzinga

U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday. The Dow traded down 0.64% to 37,741.18 whi...

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session | Benzinga

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the P...
Previous 10 Next 10